Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
D 7.84 -3.21% -0.26
ARDX closed down 3.21 percent on Monday, March 18, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
9 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -3.21%
NR7 Range Contraction -3.21%
Inside Day Range Contraction -3.21%
Oversold Stochastic Weakness -3.21%
MACD Bearish Centerline Cross Bearish -2.37%
180 Bearish Setup Bearish Swing Setup -2.37%
Stochastic Reached Oversold Weakness -2.37%
Below Lower BB Weakness -2.37%

   Recent Intraday Alerts

Alert Time
Fell Below Lower Bollinger Band about 15 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Down 3% about 15 hours ago
Lower Bollinger Band Support about 16 hours ago
Fell Below Previous Day's Low about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ardelyx, Inc. Description

Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Gastrointestinal Phosphates Kidney Disease Metabolic Disease Chronic Kidney Disease End Stage Renal Disease Renal Disease Stage Renal Disease Constipation Irritable Bowel Syndrome Molecule Therapeutics Rockwell Medical Esrd Hyperphosphatemia

Is ARDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.13
52 Week Low 3.16
Average Volume 6,575,198
200-Day Moving Average 5.33
50-Day Moving Average 8.85
20-Day Moving Average 8.85
10-Day Moving Average 8.63
Average True Range 0.51
RSI (14) 38.27
ADX 21.89
+DI 12.29
-DI 28.13
Chandelier Exit (Long, 3 ATRs) 8.30
Chandelier Exit (Short, 3 ATRs) 9.26
Upper Bollinger Bands 9.91
Lower Bollinger Band 7.79
Percent B (%b) 0.03
BandWidth 24.01
MACD Line -0.17
MACD Signal Line 0.01
MACD Histogram -0.1817
Fundamentals Value
Market Cap 1.82 Billion
Num Shares 232 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -130.67
Price-to-Sales 17.12
Price-to-Book 11.84
PEG Ratio -0.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.52
Resistance 3 (R3) 8.55 8.37 8.40
Resistance 2 (R2) 8.37 8.19 8.35 8.36
Resistance 1 (R1) 8.10 8.09 8.01 8.07 8.33
Pivot Point 7.92 7.92 7.87 7.90 7.92
Support 1 (S1) 7.65 7.74 7.56 7.62 7.35
Support 2 (S2) 7.47 7.64 7.45 7.32
Support 3 (S3) 7.20 7.47 7.28
Support 4 (S4) 7.17